Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Medpace Holdings, Inc. - Common Stock (NQ:MEDP)

465.72 +3.58 (+0.77%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 20, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Medpace Holdings, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Medpace Holdings, Inc. Reports First Quarter 2025 Results
From Medpace Holdings, Inc.
Via Business Wire
Earnings Scheduled For April 21, 2025
 
Via Benzinga
Medpace (MEDP) Q1 Earnings: What To Expect
Clinical research company Medpace Holdings (NASDAQ:MEDP) will be announcing earnings results tomorrow after market close. Here’s what you need to know. 
Via StockStory
Topics Artificial Intelligence
Insights into Medpace Hldgs's Upcoming Earnings
 
Via Benzinga
What 5 Analyst Ratings Have To Say About Medpace Hldgs
 
Via Benzinga
1 Spectacular Growth Stock Down 34% to Buy Hand Over Fist
Via The Motley Fool
Topics Initial Public Offering
3 Market-Beating Stocks with Solid Fundamentals
Companies that consistently increase their sales, margins, or returns on capital are usually rewarded with the best returns, and those that can do all three for years on end are almost always the... 
Via StockStory
1 Healthcare Stock with Solid Fundamentals and 2 to Ignore
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. But financial performance has lagged recently as players offloaded surplus COVID... 
Via StockStory
Topics Stocks
This Kraft Heinz Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Monday
 
Via Benzinga
Drug Development Inputs & Services Stocks Q4 In Review: Medpace (NASDAQ:MEDP) Vs Peers
Wrapping up Q4 earnings, we look at the numbers and key takeaways for the drug development inputs & services stocks, including Medpace (NASDAQ:MEDP) and its peers. 
Via StockStory
Medpace Holdings, Inc. to Report First Quarter 2025 Financial Results on April 21, 2025
From Medpace Holdings, Inc.
Via Business Wire
Drug Development Inputs & Services Stocks Q4 Results: Benchmarking Fortrea (NASDAQ:FTRE)
Let’s dig into the relative performance of Fortrea (NASDAQ:FTRE) and its peers as we unravel the now-completed Q4 drug development inputs & services earnings season. 
Via StockStory
A Look Back at Drug Development Inputs & Services Stocks’ Q4 Earnings: Repligen (NASDAQ:RGEN) Vs The Rest Of The Pack
As the Q4 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the drug development inputs & services industry, including Repligen (NASDAQ:RGEN) and... 
Via StockStory
Spotting Winners: Charles River Laboratories (NYSE:CRL) And Drug Development Inputs & Services Stocks In Q4
Looking back on drug development inputs & services stocks’ Q4 earnings, we examine this quarter’s best and worst performers, including Charles River Laboratories (NYSE:CRL) and its peers. 
Via StockStory
2 Reasons to Watch MEDP and 1 to Stay Cautious
Medpace has been treading water for the past six months, recording a small loss of 4.4% while holding steady at $334.43. The stock also fell short of the S&P 500’s 7.6% gain during that period. 
Via StockStory
Topics Stocks
Why Medpace (MEDP) Shares Are Trading Lower Today
Shares of clinical research company Medpace Holdings (NASDAQ:MEDP) fell 8.7% in the pre-market session after the company reported weak fourth-quarter results: Medpace's full-year revenue, EPS, and... 
Via StockStory
Harmonic Issues Weak Guidance, Joins Fluence Energy, Amkor Technology And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
 
Via Benzinga
Stay updated with the stocks that are on the move in today's after-hours session.
The regular session of the US market on Monday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements. 
Via Chartmill
Medpace Stock Falls On Q4 Earnings: The Details
Medpace Holdings Inc (NASDAQ:MEDP) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report. 
Via Benzinga
Medpace (NASDAQ:MEDP) Posts Q4 Sales In Line With Estimates But Stock Drops
Clinical research company Medpace Holdings (NASDAQ:MEDP) met Wall Street’s revenue expectations in Q4 CY2024, with sales up 7.7% year on year to $536.6 million. On the other hand, the company’s... 
Via StockStory
Medpace Holdings, Inc. Reports Fourth Quarter and Full Year 2024 Results
From Medpace Holdings, Inc.
Via Business Wire
Earnings Scheduled For February 10, 2025
 
Via Benzinga
Medpace (MEDP) To Report Earnings Tomorrow: Here Is What To Expect
Clinical research company Medpace Holdings (NASDAQ:MEDP) will be announcing earnings results tomorrow after market hours. Here’s what to expect. 
Via StockStory
Medpace Holdings, Inc. to Report Fourth Quarter and Fiscal Year 2024 Financial Results on February 10, 2025
From Medpace Holdings, Inc.
Via Business Wire
Medpace Holdings, Inc. Is Being Investigated For Securities Fraud And Investors With Losses Are Urged To Contact The Schall Law Firm
Via ACCESSWIRE
The Schall Law Firm Invites Shareholder Contributions To An Inquiry Into Medpace Holdings Inc For Securities Law Violations
Via ACCESSWIRE
Medpace Holdings, Inc. Is Being Investigated For Possible Securities Fraud And Affected Investors Are Urged To Contact The Schall Law Firm
Via ACCESSWIRE
The Schall Law Firm Invites Shareholder Participation In An Inquiry Into Medpace Holdings Inc For Securities Law Violations
Via ACCESSWIRE
Medpace Holdings, Inc. Is Being Investigated For Securities Fraud And Investors With Losses Are Urged To Contact The Schall Law Firm
Via ACCESSWIRE
10 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.